Anti-NMT2 monoclonal antibody

Anti-NMT2 antibody for FACS & in-vivo assay

Target products collectionGo to NMT2/NMT2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2217-Ab-1/ GM-Tg-hg-MP2217-Ab-2Anti-Human NMT2 monoclonal antibodyHuman
GM-Tg-rg-MP2217-Ab-1/ GM-Tg-rg-MP2217-Ab-2Anti-Rat NMT2 monoclonal antibodyRat
GM-Tg-mg-MP2217-Ab-1/ GM-Tg-mg-MP2217-Ab-2Anti-Mouse NMT2 monoclonal antibodyMouse
GM-Tg-cynog-MP2217-Ab-1/ GM-Tg-cynog-MP2217-Ab-2Anti-Cynomolgus/ Rhesus macaque NMT2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2217-Ab-1/ GM-Tg-felg-MP2217-Ab-2Anti-Feline NMT2 monoclonal antibodyFeline
GM-Tg-cang-MP2217-Ab-1/ GM-Tg-cang-MP2217-Ab-2Anti-Canine NMT2 monoclonal antibodyCanine
GM-Tg-bovg-MP2217-Ab-1/ GM-Tg-bovg-MP2217-Ab-2Anti-Bovine NMT2 monoclonal antibodyBovine
GM-Tg-equg-MP2217-Ab-1/ GM-Tg-equg-MP2217-Ab-2Anti-Equine NMT2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2217-Ab-1/ GM-Tg-hg-MP2217-Ab-2; GM-Tg-rg-MP2217-Ab-1/ GM-Tg-rg-MP2217-Ab-2;
GM-Tg-mg-MP2217-Ab-1/ GM-Tg-mg-MP2217-Ab-2; GM-Tg-cynog-MP2217-Ab-1/ GM-Tg-cynog-MP2217-Ab-2;
GM-Tg-felg-MP2217-Ab-1/ GM-Tg-felg-MP2217-Ab-2; GM-Tg-cang-MP2217-Ab-1/ GM-Tg-cang-MP2217-Ab-2;
GM-Tg-bovg-MP2217-Ab-1/ GM-Tg-bovg-MP2217-Ab-2; GM-Tg-equg-MP2217-Ab-1/ GM-Tg-equg-MP2217-Ab-2
Products NameAnti-NMT2 monoclonal antibody
Formatmab
Target NameNMT2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NMT2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NMT2 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMAP000356Human NMT2 Adenovirus particle
    ORF Viral VectorpGMAP000356Human NMT2 Adenovirus plasmid


    Target information

    Target IDGM-MP2217
    Target NameNMT2
    Gene ID9397,18108,291318,703394,487120,101090271,282049,100068766
    Gene Symbol and SynonymsA930001K02Rik,hNMT-2,NMT2
    Uniprot AccessionO60551,Q9N181
    Uniprot Entry NameNMT2_HUMAN,NMT2_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000152465
    Target ClassificationN/A

    The target: NMT2, gene name: NMT2, also named as . This gene encodes one of two N-myristoyltransferase proteins. N-terminal myristoylation is a lipid modification that is involved in regulating the function and localization of signaling proteins. The encoded protein catalyzes the addition of a myristoyl group to the N-terminal glycine residue of many signaling proteins, including the human immunodeficiency virus type 1 (HIV-1) proteins, Gag and Nef. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.